Medicare limits Aduhelm coverage to clinical trial participantsBiogen’s difficult launch of controversial Alzheimer’s therapy Aduhelm has been made even harder by a proposal by Medicare Share XMedicare limits Aduhelm coverage to clinical trial participantshttps://pharmaphorum.com/news/medicare-limits-aduhelm-coverage-to-clinical-trial-participants/
Biogen, Eisai Alzheimer’s drug lecanemab fast tracked by FDABiogen and Eisai head towards the end of the year with some much-needed good news in their Alzheimer’s Share XBiogen, Eisai Alzheimer’s drug lecanemab fast tracked by FDAhttps://pharmaphorum.com/news/biogen-eisai-alzheimers-drug-lecanemab-fast-tracked-by-fda/
Biogen takes axe to Aduhelm price in a bid to drive take-upBiogen has cut the list price of its Alzheimer’s disease therapy in half from $56,000 to $28,200 a Share XBiogen takes axe to Aduhelm price in a bid to drive take-uphttps://pharmaphorum.com/news/biogen-takes-axe-to-aduhelm-price-in-a-bid-to-drive-take-up/
Biogen’s Alzheimer’s drug Aduhelm is rejected by EU advisorsThe EMA’s human medicines committee has said it cannot approve Biogen and Eisai’s Alzheimer’s disease therapy Aduhelm, saying Share XBiogen’s Alzheimer’s drug Aduhelm is rejected by EU advisorshttps://pharmaphorum.com/news/biogens-alzheimers-drug-aduhelm-is-rejected-by-eu-advisors/
Biogen updates on its confirmatory Aduhelm trialBiogen and partner Eisai have said they will provide details next March for the confirmatory trial that will Share XBiogen updates on its confirmatory Aduhelm trialhttps://pharmaphorum.com/news/biogen-updates-on-its-confirmatory-aduhelm-trial/
Viagra ‘should be tested as Alzheimer’s therapy’Scientists in the US have found that people who use Viagra for erectile dysfunction seem to have a Share XViagra ‘should be tested as Alzheimer’s therapy’https://pharmaphorum.com/news/viagra-should-be-tested-as-alzheimers-therapy/
GSK pumps £30m into a new Oxford University partnershipGlaxoSmithKline has formed a five-year partnership with Oxford University to set up a new institute that will apply Share XGSK pumps £30m into a new Oxford University partnershiphttps://pharmaphorum.com/news/gsk-pumps-30m-into-a-new-oxford-university-institute/
Eisai forges alliance with FCNT on digital tools for dementiaJapanese drugmaker Eisai has teamed up with Fujitsu spin-out FCNT, which makes smartphones aimed at older consumers, on Share XEisai forges alliance with FCNT on digital tools for dementiahttps://pharmaphorum.com/news/eisai-forges-alliance-with-fcnt-on-digital-tools-for-dementia/
Trial of intranasal Alzheimer’s vaccine gets underway in USThe first patients are now being treated as part of a first-in-human trial of a vaccine, administered as Share XTrial of intranasal Alzheimer’s vaccine gets underway in UShttps://pharmaphorum.com/news/trial-of-intranasal-alzheimers-vaccine-gets-underway-in-us/
